[The inhalational glucocorticosteroid Inhacort in the treatment of bronchial asthma: the efficacy of long-term therapy].
The study of efficacy and safety of ingacort in severe and moderate asthma. Clinical response to ingacort, frequency of its recurrences, hospitalizations, duration of hospital stay were assessed on the treatment month 12, 24 and 36 in 58, 30 and 11 patients with bronchial asthma (BA), respectively. 12 months of ingacort treatment promoted a decline in BA symptoms: day and night episodes became less frequent, requirement of beta-2-agonists decreased, bronchial obstruction regressed. Doses of systemic steroids were reduced twice or discontinued. Asthmatic statuses occurred 10 times less frequently. This effect persisted throughout the following 2 years. Side effects were registered within the first year of the treatment and emerged after local use of the drug. Long-term administration of ingacort in bronchial asthma is safe and effective.